The abstract is read at the publisher; the summary is JClub's.
ADCdb 2.0 compiles clinical and pharmacological data for 542 antibody-drug conjugates, including >3000 curated trials and >4000 ADMET profiles, enabling antigen- and disease-centered exploration.
- Why it matters: The growing ADC clinical landscape and the need for ADMET-informed design require an integrated, evidence-backed resource to support molecular optimization and clinical development decisions.
- What they did: The team updated ADCdb with clinical landscape data for 542 ADCs, >3000 manually curated trials from nine registries/platforms, and >4000 ADMET profiles with quantitative pharmacokinetic parameters and referenced annotations.
- The result: With expanded pharmacological entries (13 088 ADC entries, 24 821 activity records) and functional annotations for 389 ADCs plus interactive visualization and search modules, ADCdb 2.0 supports rational ADC optimization.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.